|
WO2020160080A1
|
|
Oil/surfactant mixtures for self-emulsification
|
|
CN111629974A
|
|
Container cap with liner retention feature
|
|
CA3064859A1
|
|
Biopharmaceutical compositions and methods for pediatric patients
|
|
WO2018102526A1
|
|
Pharmaceutical dosage form
|
|
WO2017112838A1
|
|
METHODS OF USE OF A CLASS llA HDAC INHIBITOR
|
|
WO2017079369A2
|
|
Novel antibodies
|
|
TW201722473A
|
|
Biopharmaceutical compositions
|
|
WO2016081692A2
|
|
Substituted bridged urea analogs as sirtuin modulators
|
|
TW201620791A
|
|
Package and heat sealing device
|
|
AU2015203454A1
|
|
Benzodiazepine bromodomain inhibitor
|
|
EP3160491A1
|
|
Pharmaceutical compositions
|
|
WO2015196205A1
|
|
Method of using calcilytic compounds to treat diseases of abnormal glucose or insulin levels
|
|
AU2015203011A1
|
|
Therapeutic methods
|
|
JP2015143238A
|
|
Antibody formulations
|
|
WO2015105822A1
|
|
Cancer treatment method
|
|
AU2014277837A1
|
|
Novel adenine derivatives
|
|
CN105814413A
|
|
Metered dose container
|
|
AU2014271321A1
|
|
Purine derivatives for use in the treatment of allergic, inflammatory and infectious diseases
|
|
EP3079699A1
|
|
Treating cancer with a combination of a pd-1 antagonist and a vegfr inhibitor
|
|
AU2014340107A1
|
|
Novel compounds
|
